Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase 1, First in Human Study Investigating the Safety, Tolerability, Pharmacokinetics and Efficacy of NVG-111 in Subjects With Relapsed/Refractory ROR1+ Malignancies

NCT04763083 is registered in ClinicalTrials.gov with NovalGen Ltd. as lead sponsor.

NCT NCT04763083
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04763083 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase 1, First in Human Study Investigating the Safety, Tolerability, Pharmacokinetics and Efficacy of NVG-111 in Subjects With Relapsed/Refractory ROR1+ Malignancies
Lead sponsor
NovalGen Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
May 14, 2021
Completion date
December 31, 2025
Enrollment
90 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukaemia, diffuse large b cell lymphoma, follicular lymphoma, malignant melanoma, mantle cell lymphoma, non-small cell lung cancer (nsclc), small lymphocytic lymphoma